Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"

Ronald F. van Vollenhoven; Sander W. Tas; Michael T. Nurmohamed

doi:https://doi.org/10.1136/annrheumdis-2021-221146

Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"

Ronald F. van Vollenhoven, Sander W. Tas, Michael T. Nurmohamed

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Original language	English
Pages (from-to)	e177
Journal	Annals of the rheumatic diseases
Volume	82
Issue number	8
Early online date	13 Aug 2021
DOIs	https://doi.org/10.1136/annrheumdis-2021-221146 https://doi.org/10.1136/annrheumdis-2021-221146
Publication status	Published - 1 Aug 2023

Keywords

COVID-19
antirheumatic agents
therapeutics

Access to Document

Cite this

van Vollenhoven, R. F., Tas, S. W., & Nurmohamed, M. T. (2023). Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry". Annals of the rheumatic diseases, 82(8), e177. https://doi.org/10.1136/annrheumdis-2021-221146, https://doi.org/10.1136/annrheumdis-2021-221146

@article{0280f541380a45f99ce9cd3dd821d6d8,

title = "Correspondence on {"}Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry{"}",

keywords = "COVID-19, antirheumatic agents, therapeutics",

author = "{van Vollenhoven}, {Ronald F.} and Tas, {Sander W.} and Nurmohamed, {Michael T.}",

year = "2023",

month = aug,

day = "1",

doi = "https://doi.org/10.1136/annrheumdis-2021-221146",

language = "English",

volume = "82",

pages = "e177",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "8",

}

van Vollenhoven, RF , Tas, SW & Nurmohamed, MT 2023, 'Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"', Annals of the rheumatic diseases, vol. 82, no. 8, pp. e177. https://doi.org/10.1136/annrheumdis-2021-221146, https://doi.org/10.1136/annrheumdis-2021-221146

Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry". / van Vollenhoven, Ronald F.; Tas, Sander W.; Nurmohamed, Michael T.
In: Annals of the rheumatic diseases, Vol. 82, No. 8, 01.08.2023, p. e177.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis

T2 - results from the COVID-19 global rheumatology alliance physician registry"

AU - van Vollenhoven, Ronald F.

AU - Tas, Sander W.

AU - Nurmohamed, Michael T.

PY - 2023/8/1

Y1 - 2023/8/1

KW - COVID-19

KW - antirheumatic agents

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85164486663&partnerID=8YFLogxK

U2 - https://doi.org/10.1136/annrheumdis-2021-221146

DO - https://doi.org/10.1136/annrheumdis-2021-221146

M3 - Comment/Letter to the editor

C2 - 34389606

SN - 0003-4967

VL - 82

SP - e177

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 8

ER -

van Vollenhoven RF , Tas SW , Nurmohamed MT. Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry". Annals of the rheumatic diseases. 2023 Aug 1;82(8):e177. Epub 2021 Aug 13. doi: https://doi.org/10.1136/annrheumdis-2021-221146, https://doi.org/10.1136/annrheumdis-2021-221146

Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"

Keywords

Access to Document

Other files and links

Cite this